Related Experiment Videos
Immunoblastic lymphadenopathy associated with methyldopa therapy: a case report
Cancer
|November 1, 1978
Summary
Methyldopa therapy can trigger abnormal lymphoid proliferation, leading to immunoblastic lymphadenopathy. Symptoms resolved after drug discontinuation and responded to corticosteroid treatment.
Area of Science:
- Immunology
- Pharmacology
- Dermatology
Background:
- Drug-induced hypersensitivity reactions can manifest with diverse clinical presentations.
- Lymphoproliferative disorders require careful consideration of potential iatrogenic causes.
Observation:
- A 71-year-old woman presented with generalized weakness, lymphadenopathy, and rash during methyldopa treatment.
- Symptoms rapidly resolved upon methyldopa discontinuation, suggesting a causal link.
- The patient subsequently developed florid immunoblastic lymphadenopathy, responding to corticosteroids.
Findings:
- Methyldopa therapy was implicated in triggering an abnormal lymphoid proliferation.
- Immunoblastic lymphadenopathy can occur during or shortly after therapeutic medication administration.
- Corticosteroids demonstrated efficacy in managing the drug-induced lymphadenopathy.
Implications:
- This case highlights the importance of considering drug-induced lymphoproliferative disorders in patients presenting with unexplained lymphadenopathy and rash.
- Clinicians should maintain a high index of suspicion for medication-related adverse events.
- Differential diagnosis of lymphadenopathy should include drug-induced conditions.